Consumer Brief Summary News Today

- AbbVie will present 15 abstracts, including three oral presentations, in Crohns disease and ulcerative colitis reinforcing AbbVies commitment to advancing...

– A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVies commitment to produce a portfolio of products that aim to improve the lives of patients...

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohns...

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult...

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission and key secondary endpoints as an induction and maintenance...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023,...

Treatment with SKYRIZI (risankizumab) demonstrated short- and long-term efficacy of psoriasis signs and symptoms (sPGA 0/1) at week 16 and week 52 in a...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...

A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVies commitment to research that helps advance standards of...

(BPT) - *Gina is an actual SKYRIZI patient, compensated by AbbVie for sharing her story.